Search

Cell biologist Philipp Niethammer discusses what the zebrafish can teach us about how the body heals.

… Wednesday, July 15, 2015 VIDEO | 00:04 Watch: The Body’s Immune Response In Action Video Details Summary An overactive immune system can lead to diseases, including cancer. In this Q&A, cell biologist Philipp Niethammer talks about his work studying inflammation and wound repair in zebrafish. Highlights

At MSK we have developed a highly accurate, low-cost assay, for identifying early-stage oral and anal cancers associated with human papillomavirus (HPV) using liquid biopsy.

… Tuesday, December 10, 2019 Together with my colleagues at Memorial Sloan Kettering Cancer Center, we developed a highly accurate assay for identifying early-stage oral and anal cancers associated with human papillomavirus (HPV) using liquid biopsy. This low-cost technique could be advantageous in early

Learn about the Chief Strategy Officer at MSK, Anaeze Offodile, MD, MPH.

… Tuesday, September 3, 2024 “We are in a moment of historic change in cancer care,” says Anaeze Offodile, MD, MPH . Dr. Offodile joined Memorial Sloan Kettering Cancer Center (MSK) in 2023 as Chief Strategy Officer, after serving as the Executive Director for Clinical Transformation at MD Anderson. Among

— Researchers from Memorial Sloan Kettering Cancer Center (MSK) have shown early promising results in using a chimeric antigen receptor (CAR) T cell therapy that targets the protein mesothelin, which is expressed on the surface of cancer cells in patients with diseases of the chest cavity — namely malignant pleural mesothelioma but also metastatic lung and breast cancer. The results from a phase I clinical trial were presented as part of the press program at the American Association for Cancer Research (AACR) Annual Meeting 2019. The findings showed tumor reduction in patients who participated in the study and no evidence of toxicity.

… Sunday, March 31, 2019 Researchers from Memorial Sloan Kettering Cancer Center (MSK) have shown early promising results in using a chimeric antigen receptor (CAR) T cell therapy that targets the protein mesothelin, which is expressed on the surface of cancer cells in patients with diseases of the chest

The U.S. Food and Drug Administration (FDA) has granted full approval to the drug tarlatamab, a bispecific T cell engager, for small cell lung cancer, based on results from a phase 3 clinical trial led by Dr. Charles Rudin at MSK.

… Thursday, November 20, 2025 On November 19, 2025, the U.S. Food and Drug Administration (FDA)  granted full approval  to the targeted immunotherapy drug  tarlatamab (Imdelltra ® )  for treating adults with advanced small cell lung cancer (SCLC) that has spread after platinum-based chemotherapy. The approval

In a plenary presentation at the 2024 American Association for Cancer Research (AACR) Annual Meeting, Dr. Dana Pe’er highlighted three recent research collaborations between her lab and other labs at MSK that have shed new light on the ability of cancer cells to adapt and spread.

… Tuesday, April 9, 2024 About 90% of deaths from cancer are a result of metastasis — that is, from cancer’s ability to spread from an initial primary tumor to seed new tumors throughout the body, often in the lungs, liver, and brain. And metastasis relies on cancer cells’ ability to adapt to different

The US Food and Drug Administration (FDA) announced today the authorization of MSK-IMPACT™ (which stands for integrated mutation profiling of actionable cancer targets), a high throughput, targeted-DNA-sequencing panel for somatic mutations. Created by the Department of Pathology at Memorial Sloan Kettering Cancer Center (MSK), MSK-IMPACT is a 468-gene oncopanel intended to detect gene mutations and other critical genetic aberrations in both rare and common cancers.

… Wednesday, November 15, 2017 The US Food and Drug Administration (FDA) announced today the authorization of MSK-IMPACT ™ (which stands for integrated mutation profiling of actionable cancer targets), a high throughput, targeted-DNA-sequencing panel for somatic mutations. Created by the Department of

For the first time, a targeted drug is showing promise at treating non-small cell lung cancer caused by a mutation called KRAS-G12D.

… Sunday, April 27, 2025 For decades, cancers with mutations in the gene  KRAS (KAY-ras) were considered “undruggable.”  KRAS  mutations are found in more than 20% of cancers. They are most common in  lung cancer ,  pancreatic cancer , and  colorectal cancer . Nearly four years ago, the first drug was

Por primera vez, un fármaco dirigido está mostrando resultados prometedores en el tratamiento del cáncer pulmonar de células no pequeñas causado por una mutación llamada KRAS-G12D.

… Sunday, April 27, 2025 Durante décadas, los casos de cáncer con mutaciones en el gen  KRAS  se consideraron “no tratables con fármacos”. Las mutaciones en KRAS  se encuentran presentes en más del 20 % de los casos de cáncer. Son más comunes en el  cáncer pulmonar ,  el cáncer de páncreas y el  cáncer

The collective efforts of the “TeamLabs” will accelerate discoveries in glioblastoma, ovarian, and pancreatic cancers

… Tuesday, April 19, 2022 Today, one year after its founding, Break Through Cancer has awarded Memorial Sloan Kettering Cancer Center (MSK) more than $12 million in grants to intercept cancer at the earliest stages and find cures to several of the deadliest cancers. This funding is part of a total of $50